Theriva™ biologics reports full-year 2024 operational highlights and financial results

– enrollment completed in virage phase 2b clinical trial of vcn-01 in metastatic pancreatic ductal adenocarcinoma (pdac); topline data expected in q2 2025 –

TOVX Ratings Summary

TOVX Quant Ranking